MDACC 2018: An Update on the Treatment of M0 CRPC

November 10, 2018

Houston, TX (UroToday.com) Within the past year the landscape of M0 CRPC has changed dramatically on the heels of 2 studies using early administration of 2nd generation androgen receptor blockers. Both apalutamide and enzalutamide have multiple inhibitor mechanisms for the AR receptor and have been accepted in the metastatic setting.

In separate landmark trials, each drug was able to improve metastasis-free survival (MFS), disease-specific, and overall survival1, 2. On deeper analysis, longer doubling time (>6months) was found to be an important predictor of response to therapy, but even when <6 months a benefit was demonstrable. Dr. Aparacio points out the discordance between the strict definition of M0 and what we observe anecdotally as slightly enlarged lymph nodes that do not meet size criteria for metastasis.

She cautions that not all M0 CRPC patients should be started on therapy at the first sign of PSA elevation since both of the available medications have the potential to cause serious adverse events, including an increased risk of falls that can be catastrophic in an elderly population.

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.